505 (b) (2) approvals in May 2025

There are three 505(b)(2) NDAs approved by the USFDA and one NDA that received tentative approval from the USFDA in May 2025. The details are as follows.


More details can also be found in the API and IP newsletter published by us. 


Comments

Post a Comment

Popular posts from this blog

FDA alerts drug manufacturers to the risk of benzene contamination in certain drugs

Image
The FDA is investigating the root cause of benzene contamination in certain drugs and informing drug manufacturers about the risks associated with benzene contamination from drug components and other potential factors. Here's a summary of the FDA's alert to drug manufacturers regarding the risk of benzene contamination in certain drugs: Key Concerns: Benzene Contamination: The FDA is alerting drug manufacturers to the potential risk of benzene contamination in drug products. Benzene is a known human carcinogen. Root Cause Evaluation: The FDA is evaluating the root cause of benzene contamination in certain drugs and alerting drug manufacturers to the risk of benzene contamination from drug components. Recalls: Certain drug products, including hand sanitisers, benzoyl peroxide products, and aerosol drug products, have been recalled due to benzene contamination. Manufacturer Responsibilities: Testing: Drug manufacturers are required to establish scientifically sound and appr...
Read more

The Central Drugs Standard Control Organisation(CDSCO) issued a circular for Nitrosamines in Ranitidine

NDMA, also known as N-Nitrosodimethylamine, and other nitrosamines are significant concerns for the pharmaceutical industry. USFDA and other health agencies, especially in strict regulatory markets (SRM), require nitrosamine risk assessments in the dossiers submitted to the respective authorities.  Many countries have banned the drug products which would have the potential to form nitrosamines during the manufacturing process or storage. Ranitidine is one of them. CDSCO has also recently issued a circular on 12 July 2025. The circular can be found here .  The circular addresses concerns about NDMA impurity in Ranitidine. It informs State/UT Drug Controllers of recommendations from the Drugs Technical Advisory Board (DTAB), following a report by an expert committee.  The DTAB recommends forming a larger committee to examine all aspects of Ranitidine, the ICMR (Indian Council of Medical Research) conducting a safety assessment on NDMA impurity, and manufacturers monitoring ...
Read more

FDA form 483 observations: NATCO Pharma

FDA form 483 observations: NATCO Pharma General Information: • Company: NATCO Pharma Limited, Pharma Division, Kothur Village, Rangareddy,           Telangana, India • Inspection Dates: 06/09/2025 - 06/19/2025 • Products manufactured: Sterile and Non-Sterile Drug Manufacturers   Oral solid dosages, including Cytotoxic Orals Cytotoxic Injectables Pre-filled Syringes Key Observations: 1. Environmental Monitoring Deficiencies (Observation 1): The firm's system for monitoring environmental conditions in aseptic processing areas is deficient. Electronic data for non-viable particle (NVP) counts used in environmental monitoring and cleanroom qualification is not adequately reviewed. Discrepancies exist between electronic data and official hardcopy results for NVP, affecting multiple batches between 11/02/2023 and 04/16/2024, where results were altered. Operators saved data on USB drives, potentially allowing data manipulation, which indicates a gap in dat...
Read more